MTNB Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Matinas BioPharma Holdings Inc (MTNB) is not a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company is facing significant financial challenges, including non-compliance with NYSE listing standards, continuous losses, and poor financial performance. Technical indicators and trading trends do not support a bullish outlook, and there are no positive catalysts or signals to justify an investment at this time.
The MACD is below 0 and negatively contracting, the RSI is neutral at 36.084, and the moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading below the pivot level of 0.549, with support at 0.492 and resistance at 0.606. Overall, the technical indicators suggest a bearish outlook.
NULL identified.
The company received a compliance notice from NYSE American for insufficient shareholder equity, reported continuous losses over the past five fiscal years, and must submit a compliance plan by May 2, 2026, to regain compliance within 18 months. Additionally, the company has failed to meet minimum equity requirements.
In Q4 2025, the company reported zero revenue, a net income loss of -$2.53 million (down 70% YoY), and an EPS of -0.4 (down 75.9% YoY). Gross margin remained at 0%. The financial performance indicates significant challenges and no growth.
No recent analyst ratings or price target changes are available.
